butyrate sustained release (BKR-017) / BioKier - LARVOL DELTA

Pharmacokinetics of Butyrate Tablet BKR-017 (clinicaltrials.gov) - P=N/A | N=10 | Recruiting | Sponsor: BioKier Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Aug 2025 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • Dyslipidemia • Metabolic Disorders

Butyrate Adjuvant Therapy for Type 1 Diabetes (clinicaltrials.gov) - P1/2 | N=20 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Apr 2025 ➔ Dec 2025

Trial completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Pharmacokinetics of Butyrate Tablet BKR-017 (clinicaltrials.gov) - P=N/A | N=10 | Not yet recruiting | Sponsor: BioKier Inc. | Trial completion date: Mar 2025 ➔ Aug 2025 | Initiation date: Sep 2024 ➔ Jun 2025 | Trial primary completion date: Feb 2025 ➔ Jul 2025

Trial completion date • Trial initiation date • Trial primary completion date • Dyslipidemia • Metabolic Disorders

Butyrate Adjuvant Therapy for Type 1 Diabetes (clinicaltrials.gov) - P1/2 | N=20 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2025 ➔ Apr 2025 | Trial primary completion date: Oct 2024 ➔ Apr 2025

Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus